TNF and psoriasis vulgaris: Secukinumab was the most frequently used biologic drug, followed by ustekinumab, tumor necrosis factor (TNF) inhibitors, and ixekizumab, a ranking that roughly corresponds to the prescription trends for moderate-to-severe plaque psoriasis in Italy [39].